Methods for treating covid-19 with sepiapterin
Inventors
CLARK, Gene Chatman • MEZZAROMA, Eleonora • RABENDER, Christopher • MIKKELSEN, Ross B. • YAKOVLEV, Vasily • Smith, Neil
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12691119-B2
Publication Date
2026-07-28
Expiration Date
Abstract
The invention features methods of treating a SARS-CoV-2 infection in a subject, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.
Core Innovation
The invention describes therapeutic treatment of SARS-CoV-2 infection in a human subject by administering sepiapterin or a pharmaceutically acceptable salt, with the method directed to mitigating acute respiratory distress. The described embodiments also address sepsis and fibrotic disease resulting from acute respiratory distress. The provided content identifies these treatment outcomes but does not include the patent's background section.
The proposed biological rationale is suppression of lung inflammation while promoting adaptive immunity. The partial content reports reduced lung cytokine levels in an LPS-induced lung inflammation model and increased CD8+ T-cell proliferation in vitro and in vivo, with limited direct effects on T-cell activation and cytokine production. The specific problem stated in the background is not explicitly described in the provided content.
Claims Coverage
One independent claim is identified. Its coverage comprises three central features, with dependent claims further refining the treatment and adding related outcomes.
Treatment of SARS-CoV-2 infection in a human subject
The independent claim covers a method of therapeutic treatment of a SARS-CoV-2 infection in a human subject in need thereof.
Administration of sepiapterin or a pharmaceutically acceptable salt
The method comprises administering an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.
Mitigation of acute respiratory distress
The method comprises mitigating acute respiratory distress associated with the claimed treatment.
Refinements to treatment and related outcomes
The dependent claims refine the treatment with administration and formulation limitations and include mitigation of sepsis or fibrotic disease resulting from acute respiratory distress.
The claim coverage centers on treating SARS-CoV-2 infection with sepiapterin or its pharmaceutically acceptable salt to mitigate acute respiratory distress, with dependent claims specifying treatment refinements and related conditions.
Stated Advantages
The treatment is directed to mitigating acute respiratory distress associated with SARS-CoV-2 infection.
The described embodiments also address mitigation of sepsis and fibrotic disease resulting from acute respiratory distress.
Documented Applications
Therapeutic treatment of SARS-CoV-2 infection in a human subject, with the stated outcome of mitigating acute respiratory distress.
The described embodiments also address sepsis and fibrotic disease resulting from acute respiratory distress.
Interested in licensing this patent?